Citadel Advisors’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $146K | Buy |
+32,400
| New | +$142K | ﹤0.01% | 11709 |
|
|
2025
Q4 | – | Sell |
-30,600
| Closed | -$139K | – | 12516 |
|
|
2025
Q3 | $139K | Sell |
30,600
-40,600
| -57% | -$149K | ﹤0.01% | 11591 |
|
|
2025
Q2 | $220K | Buy |
71,200
+33,300
| +88% | +$111K | ﹤0.01% | 10477 |
|
|
2025
Q1 | $132K | Sell |
37,900
-12,500
| -25% | -$41.7K | ﹤0.01% | 11060 |
|
|
2024
Q4 | $165K | Sell |
50,400
-3,900
| -7% | -$14.3K | ﹤0.01% | 10744 |
|
|
2024
Q3 | $209K | Buy |
54,300
+30,600
| +129% | +$117K | ﹤0.01% | 10055 |
|
|
2024
Q2 | $73.2K | Sell |
23,700
-69,400
| -75% | -$208K | ﹤0.01% | 11319 |
|
|
2024
Q1 | $240K | Sell |
93,100
-15,800
| -15% | -$40.9K | ﹤0.01% | 9939 |
|
|
2023
Q4 | $272K | Buy |
108,900
+12,700
| +13% | +$24.9K | ﹤0.01% | 9346 |
|
|
2023
Q3 | $195K | Sell |
96,200
-13,300
| -12% | -$27.9K | ﹤0.01% | 9961 |
|
|
2023
Q2 | $252K | Sell |
109,500
-55,800
| -34% | -$145K | ﹤0.01% | 9392 |
|
|
2023
Q1 | $501K | Sell |
165,300
-67,700
| -29% | -$191K | ﹤0.01% | 8305 |
|
|
2022
Q4 | $543K | Buy |
233,000
+14,200
| +6% | +$34K | ﹤0.01% | 8066 |
|
|
2022
Q3 | $418K | Buy |
218,800
+4,700
| +2% | +$11.1K | ﹤0.01% | 8855 |
|
|
2022
Q2 | $580K | Sell |
214,100
-68,200
| -24% | -$175K | ﹤0.01% | 8304 |
|
|
2022
Q1 | $841K | Sell |
282,300
-78,600
| -22% | -$241K | ﹤0.01% | 8107 |
|
|
2021
Q4 | $1.4M | Sell |
360,900
-135,100
| -27% | -$525K | ﹤0.01% | 7044 |
|
|
2021
Q3 | $2.13M | Buy |
496,000
+321,200
| +184% | +$1.07M | ﹤0.01% | 6188 |
|
|
2021
Q2 | $530K | Buy |
174,800
+56,100
| +47% | +$174K | ﹤0.01% | 9935 |
|
|
2021
Q1 | $395K | Sell |
118,700
-3,100
| -3% | -$12K | ﹤0.01% | 10202 |
|
|
2020
Q4 | $432K | Buy |
121,800
+7,100
| +6% | +$24.9K | ﹤0.01% | 8407 |
|
|
2020
Q3 | $359K | Buy |
114,700
+89,100
| +348% | +$271K | ﹤0.01% | 7832 |
|
|
2020
Q2 | $47K | Buy |
+25,600
| New | +$41.9K | ﹤0.01% | 9328 |
|
|
2020
Q1 | – | Sell |
-10,900
| Closed | -$30K | – | 9518 |
|
|
2019
Q4 | $30K | Buy |
+10,900
| New | +$17.6K | ﹤0.01% | 8864 |
|
|
2019
Q1 | – | Sell |
-16,500
| Closed | -$63K | – | 9190 |
|
|
2018
Q4 | $63K | Buy |
+16,500
| New | +$81.3K | ﹤0.01% | 8421 |
|
|
2016
Q1 | – | Sell |
-9,600
| Closed | -$43K | – | 6636 |
|
|
2015
Q4 | $43K | Sell |
9,600
-2,800
| -23% | -$15.3K | ﹤0.01% | 7424 |
|
|
2015
Q3 | $76K | Sell |
12,400
-1,200
| -9% | -$10.6K | ﹤0.01% | 7220 |
|
|
2015
Q2 | $161K | Sell |
13,600
-1,300
| -9% | -$19.8K | ﹤0.01% | 6583 |
|
|
2015
Q1 | $260K | Sell |
14,900
-13,500
| -48% | -$277K | ﹤0.01% | 5846 |
|
|
2014
Q4 | $430K | Sell |
28,400
-27,000
| -49% | -$466K | ﹤0.01% | 4928 |
|
|
2014
Q3 | $1.17M | Buy |
55,400
+51,100
| +1,188% | +$834K | ﹤0.01% | 3508 |
|
|
2014
Q2 | $56K | Buy |
+4,300
| New | +$61K | ﹤0.01% | 6672 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Citadel Advisors's ABUS Position: Q1 2026 in Review
Citadel Advisors increased its Arbutus Biopharma (ABUS) stake by 546% in Q1 2026, buying an estimated $2.5M and bringing the position to 677,138 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #5232.
Citadel Advisors first reported a position in ABUS in Q2 2014 and has held it in 41 quarters since. The position peaked at $6.29M in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Citadel Advisors held 677,138 shares of Arbutus Biopharma worth $3.05M as of Q1 2026.
- Citadel Advisors bought 572,295 Arbutus Biopharma shares in Q1 2026, an estimated $2.5M.
- Arbutus Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5232 holding.
- Citadel Advisors first reported a position in Arbutus Biopharma in Q2 2014 and has held it in 41 quarters since.
- Citadel Advisors's Arbutus Biopharma position peaked at $6.29M in Q1 2015.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.